Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A. Neuschwander‐Tetri, Edward Doo, Mark L. Van Natta et al.|The Lancet|2014Cited by 2.2k
In vivo Bruton’s tyrosine kinase inhibition attenuates alcohol-associated liver disease by regulating CD84-mediated granulopoiesisPrashanth Thevkar Nagesh, Bruce Barton, Yeonhee Cho et al.|Science Translational Medicine|2024Cited by 8